Research programme: adenosine A2 receptor antagonists - Almirall SA/Neurocrine Biosciences
Alternative Names: NBI 80649Latest Information Update: 28 Feb 2011
Price :
$50 *
At a glance
- Originator Almirall-Prodesfarma; Neurocrine Biosciences
- Developer Almirall S.A.; Neurocrine Biosciences
- Class Small molecules
- Mechanism of Action Adenosine A2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Huntington's disease; Parkinson's disease
Most Recent Events
- 28 Feb 2011 Development discontinued for Huntington's disease before 2011
- 28 Feb 2011 Development discontinued for Parkinson's disease before 2011
- 07 Nov 2007 Pharmacodynamics and adverse events data from a preclinical study in Parkinson's disease presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007)